TrialJournal of gastroenterology2018

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Hiromitsu Kumada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.